In a phase II DBRPCT, Cenerimod (sphingosine-1-phosphate recptr modulator) was not shown effective (vs PBO) at 12 mos in active, SLE pts. CARE study enrolled 427 SLE pts who were randomized to Placebo or 3 different doses of CEN - primary endpoint was not met.… https://t.co/AR6NsEsv8S https://t.co/i89ANl5dai